BRIDGEWAY CAPITAL MANAGEMENT, LLC
Position in LYEL — Lyell Immunopharma, Inc.
CIK 1107261
HOUSTON, TX
Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$361,080
-$192,960 QoQ
Shares Held
18,000
0.0% QoQ
Ownership
0.077%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $59,315,164 across 112 Biotechnology names. LYEL ranks #48 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GLUE |
Monte Rosa Therapeutics, Inc.
|
528,698 | $8,697,082 | |
| 2 | PBYI |
Puma Biotechnology, Inc.
|
775,341 | $4,954,428 | |
| 3 | EXEL |
Exelixis, Inc.
|
66,100 | $2,835,029 | |
| 4 | KROS |
Keros Therapeutics, Inc.
|
195,017 | $2,152,987 | |
| 5 | SGMT |
Sagimet Biosciences Inc.
|
299,641 | $1,565,624 | |
| 6 | BDTX |
Black Diamond Therapeutics, Inc.
|
723,477 | $1,541,006 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
22,000 | $1,498,860 | |
| 8 | KYTX |
Kyverna Therapeutics, Inc.
|
149,900 | $1,293,637 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $361,080 | 18,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $554,040 | 18,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $292,320 | 18,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $159,120 | 18,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||